BIOPHARMACEUTICAL company Secarna Pharmaceuticals has entered into a co-development agreement with Firebrand Therapeutics using their combined resources and specific expertise in pursuing "novel targets playing a key role in cancer metastasis".
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Sep 18
